<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6555">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03021590</url>
  </required_header>
  <id_info>
    <org_study_id>G5-17</org_study_id>
    <nct_id>NCT03021590</nct_id>
  </id_info>
  <brief_title>Comparison Efficacy of 14-day Triple Therapy:Clarithromycin vs.Sequential in Eradication of H.Pylori</brief_title>
  <official_title>Comparison Efficacy of 14-day Triple Therapy:Clarithromycin vs. Sequential Therapy With Clarithromycin in Eradication of H. Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damascus Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damascus Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison Efficacy of 14-day Triple Therapy between levofloxacin and sequential therapy
      with levofloxacin on the Eradication of Helicobacter Pylori in Syrian population
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 5, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate according to Intention to treat (ITT) and per-protocol (PP) analysis</measure>
    <time_frame>6 weeks after eradication therapy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Helicobacter Pylori Gastrointestinal Tract Infection</condition>
  <arm_group>
    <arm_group_label>Sequential Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin 1000 mg,Tablets and Esomeprazole 40 mg Capsule each every 12 hours for 7days for 7 days all by mouth then Clarithromycin 500 mg Tablets and Esomeprazole 40 mg Capsule and Tinidazole 500 mg Tablets each every 12 hours for 7 days all by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 500 mg Tablets and Esomeprazole 40 mg Capsule and Amoxicillin 1000 mg , Tablets every 12 hours for 14 days all by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinidazole 500Mg Tablet</intervention_name>
    <description>Amoxicillin 1000 mg Tablets every 12 hours for 7days and Esomeprazole 40 mg Capsule for 7 days all by mouth then Clarithromycin 500 mg Tablets and Esomeprazole 40 mg Capsule by mouth and Tinidazole 500 mg Tablets every 12 hours for 7 days all by mouth</description>
    <arm_group_label>Sequential Therapy</arm_group_label>
    <other_name>Clarithromycin 500Mg Tablet</other_name>
    <other_name>Esomeprazole 40Mg Capsule</other_name>
    <other_name>Amoxicillin 1000Mg Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 500Mg Tablet</intervention_name>
    <description>Clarithromycin 500 mg Tablets and Esomeprazole 40 mg Capsule and Amoxicillin 1000 mg Tablets every 12 hours all by mouth for 14 days</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <other_name>Esomeprazole 40Mg Capsule</other_name>
    <other_name>Amoxicillin 1000Mg Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any
        of following three methods: I-Positive rapid urease test (CLOtest). II-Histologic evidence
        of H. pylori by modified Giemsa staining. III-Positive 13C-urea breath test. without prior
        eradication therapy and are willing to receive therapy.

        Exclusion Criteria:

          -  Children and teenagers aged less than 18 years.

          -  Previous eradication treatment for H. pylori.

          -  Patients who took any drug, which could influence the study results such as proton
             pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.

          -  History of gastrectomy.

          -  Gastric malignancy, including adenocarcinoma and lymphoma,

          -  Previous allergic reaction to antibiotics (Amoxicillin, Tinidazole , Levofloxacin)
             and prompt pump inhibitors (Es-omeprazole).

          -  Contraindication to treatment drugs.

          -  Pregnant or lactating women.

          -  Severe concurrent disease. Liver cirrhosis. Chronic kidney disease.

          -  Patients who cannot give informed consent by himself or herself.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marouf M Alhalabi, MD</last_name>
    <phone>+96311952781278</phone>
    <email>e.marouf@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damascus Hospital</name>
      <address>
        <city>Damascus</city>
        <zip>+963</zip>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 5, 2017</lastchanged_date>
  <firstreceived_date>January 5, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Helicobacter Infections</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <keyword>sequential therapy</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Tinidazole</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
